Background: Tacrolimus, commonly used for graft versus host disease prophylaxis is usually administered via a dedicated central venous line (CVL) and trough levels drawn from the unexposed lumen. Being an oil-based medication, it may be adsorbed to the inner lumen of the CVL and result in falsely high levels drawn from an inadvertently exposed lumen. There is no treatment for decontamination of such CVLs, and natural decay occurs over months before the CVL can be used to draw reliable trough levels. Objective: The primary objective of the study was to estimate the effectiveness of 70% ethanol locks for decontaminating CVLs exposed to tacrolimus. Methods: We studied the efficacy of 70% ethanol lock in decontaminating CVLs exposed to tacrolimus in patients during transplant. Trough tacrolimus levels were drawn from the exposed and unexposed (control) lumens at 8:00 am, followed by a 2-mL 70% ethanol lock instilled for a 2-hour dwell into the exposed (intervention) lumen. Trough tacrolimus levels were again drawn from both lumens at 8:00 pm and levels compared for efficacy. Results: All 20 sets showed a high 8 am trough level in the exposed intervention arm (median = 30 ng/mL), significantly greater (P < 0.0001) than that in the control arm (median = 9.05 ng/mL), and were contaminated. After the 2-hour ethanol lock, 65% of the lumens were decontaminated. The difference between the control and intervention arms was no longer found to be statistically significant (P = 0.0826). Conclusion: A 2-hour 70% ethanol lock is effective for decontamination of CVLs exposed to tacrolimus.
Introduction
Graft versus host disease (GvHD) is a common complication after an allogeneic hematopoietic stem cell transplant (HSCT), and calcineurin inhibitors (CNIs) along with methotrexate are the standard of care for GVHD prophylaxis. 1 Patients undergoing HSCT usually have a double lumen central venous line (CVL), with one lumen dedicated to administer the CNI and the other (unexposed to CNIs) to measure trough CNI levels, besides other uses. Tacrolimus and cyclosporine A are oilbased medications and can be adsorbed to the inner lumen of the CVL catheter. Many studies have demonstrated that trough CNI levels drawn through a lumen exposed to CNIs can be falsely elevated, complicating the medical decision making (MDM) process. 2, 3 As the levels could be up to 8 times higher than those from the unexposed lumen; it is standard practice that trough CNI levels are not measured from blood drawn from a lumen used to infuse the CNI. 3, 4 A retrospective analysis at Nationwide Children's Hospital's (NCH's) HSCT unit over a 2-year period (2010) (2011) (2012) showed that 17% of the unexposed CVL lumens were contaminated with a CNI during the life of a CVL (personal communication, unpublished data). Once a CVL lumen is contaminated, the only alternative to ensure accurate trough CNI levels is to obtain a peripheral blood sample via a needle stick. 3 Continued use of such contaminated CVL lumens leads to natural decay of the adsorbed CNI over many weeks to months; however, until then, peripheral blood samples have to be collected. This can cause additional physical and/or mental trauma to the patient and the family. Moreover, the need to perform additional trough CNI levels results in added financial burden to the patient and increased resource use for medical centers. There is no known published method or process reported for decontamination of CNI-exposed CVLs.
Miscibility is the ability of 2 or more liquids to mix and form an even solution; thus, substances with bipolar molecules will dissolve with other substances with bipolar molecules. Intravenous cyclosporine is formulated in polyoxyethylated castor oil and alcohol and intravenous tacrolimus is formulated in polyoxyl-hydrogenated castor oil and alcohol. 5, 6 Because alcohol (70% ethanol), a bipolar solvent, is easily miscible with these solvents, we hypothesized that a 70% ethanol lock instilled into the CVL lumen will elute out the oil-based CNI adsorbed to the inner lumen of the CVL, thus decontaminating it and making it reusable for drawing trough CNI levels.
Safety of using 70% ethanol in CVLs has already been proven in multiple studies using ethanol locks to prevent or treat CVL-related bacterial infections in pediatrics. [7] [8] [9] [10] Ethanol and hydrochloric acid locks have also been used for clearing CVLs occluded with lipid and/or drug precipitates. 11 Crnich et al 12 exposed polyurethane and silicone catheters to 70% ethanol for as long as 10 weeks and did not find any reductions in the mechanical integrity of the CVLs. Studies have also shown that small volumes of ethanol are tolerated by pediatric patients without any untoward effects. 9 However, there are no previous studies on the use of 70% ethanol for decontamination of CVLs exposed to CNIs, which is a commonly encountered problem in BMT patients. The primary objective of this study was to estimate the efficacy of 70% ethanol locks for decontaminating CVLs exposed to tacrolimus. The secondary objective was to estimate the incidence of adverse effects of ethanol locks in the study population.
Methods and Statistics
This prospective study was approved by the institutional review board (IRB14-00028). A total of 11 patients (contributing 20 sample sets) between the ages of 3 months and 30 years undergoing allogeneic HSCT were included in the study after informed consent. Patients who were hemodynamically compromised or in the intensive care unit were excluded from the study. The standard practice at our institution is to administer intravenous tacrolimus over a period of 120 minutes starting from day −3 of HSCT via the white lumen of the CVL (labeled as exposed to CNIs) and to obtain trough levels via the red lumen (never exposed to CNIs). The starting dose of tacrolimus (Prograf) is 0.015 mg/kg/dose intravenously every 12 hours, each dose infused over 2 hours. The doses are scheduled to be administered at 08:00 and 20:00 hours. For this study, the red lumen was labeled as the control arm of the study and the white lumen (exposed to tacrolimus and, hence, contaminated lumen) was marked as the intervention arm. Per standard practice, we measure trough tacrolimus levels twice a week (every Monday and Thursday). For this study, trough tacrolimus levels were drawn from both lumens at 8:00 am on the first Monday or Thursday after day −3, followed by infusion of tacrolimus via the white lumen per standard practice. A 2-mL 70% ethanol was then instilled for 2 hours in the white lumen only (intervention arm) and allowed to dwell. At the end of 2 hours, ethanol was removed; the lumen flushed with 0.9% sodium chloride, and normal use of the CVL was resumed. To measure the efficacy of the ethanol intervention, trough tacrolimus levels were again drawn from the control and intervention arms at 8:00 pm, before infusing the evening dose of tacrolimus. The 2 levels drawn at 8 am and at 8 pm constituted 1 data set and were labeled as A1/B1 and A2/B2, respectively, as shown in Figure 1 . Patients are relatively stable during the first 2 weeks of admission for transplant, and CVL use increases once they develop mucositis or febrile neutropenia. Hence, the first data set was collected on the first Monday or Thursday after the start of tacrolimus, and additional data set(s) were collected subsequently if the CVL was still available for the ethanol lock. The procedural methods for the ethanol lock and the flow diagram to illustrate the schema of the study are shown in Figure 1 .
Tacrolimus was measured in the clinical laboratory at NCH on the Abbott Architect by a one-step chemiluminescent microparticle immunoassay in whole blood following a protein-precipitation pretreatment with methanol and zinc sulfate, according to the manufacturer's recommendations. The 120-day running assay precision is defined by 3 levels of quality control materials as follows: level 1, mean = 4.6 ng/mL, SD = 0.22, coefficient of variance (CV) = 4.7%; level 2, mean = 8.6 ng/mL, SD = 0.38, CV = 4.4%; level 3, mean = 17.4 ng/mL, SD = 0.79, CV = 4.5%. The analytical measurement range of the tacrolimus assay is 2 to 30 ng/ mL, with sample dilution permitting reporting up to 60 ng/ mL; we follow a clinical range of 8 to 14 ng/mL for therapeutic dose adjustments. An analytically significant change is defined as exceeding the significant change limit (SCL), which is the Initial value/Control value ± 2.8 × The assay analytical CV. 13 Because all 3 levels of tacrolimus quality control (mentioned above) had nearly the same variance (percentage CVs ranging from 4.4% to 4.7%), with an average of 4.5%, the average percentage CV was used to represent assay analytical variance. Using this average, the SCL for this study was defined by the following equation: SCL = 4.5% 2.8 = 12.6% × ± Thus, any change from the control ±12.6% was considered analytically significant. Trough tacrolimus levels from both lumens drawn at 8:00 am (A1 and B1) were compared with levels drawn at 8:00 pm (A2 and B2). Because of lack of preliminary data on how the intervention would affect the trough levels, conservative assumptions were made to look for large effect sizes. With 20 control-intervention sample pairs and 5% type II error, we would have approximately 80% power to detect a large difference between the 8 pm control and 8 pm intervention tacrolimus levels using a nonparametric Wilcoxon signed-rank test. The study was set up to analyze data after 20 pairs of data sets were collected, regardless of whether they came from the same patient or not. Data were summarized with descriptive statistics. Data were analyzed to be compared based on analytical reference ranges with SCL, and additional analysis was done based on the clinical reference range used for MDM. Comparisons between control and intervention arms were assessed using nonparametric methods. Analysis was not performed at the patient level but rather at the observation level because the overall aim of the study was to see if existing contamination could be removed with an ethanol lock; also, because every observation had its own comparative control, each patient could provide multiple sets of data. The aspect of how tacrolimus level varies as a result of biological differences was not of interest; thus, the lack of truly independent sets of observations was not a large concern. All statistical analyses were performed using SAS, version 9.3 (SAS Institute, Cary, NC).
A lumen of a CVL was considered to be potentially contaminated with CNIs if CNIs had been infused through that lumen or if a high trough level obtained from that lumen could not be clinically justified. The ethanol intervention was considered effective in decontaminating a CVL lumen, if the 8 pm tacrolimus level from the intervention lumen (B2) was within the SCL of the control arm (A2) at 8 pm and/or if the 8 pm tacrolimus level fell by more than 30% as compared with the morning level. The ethanol intervention was considered partially effective if the 8 pm tacrolimus level (B2) decreased by a value equal to or greater than the SCL of the intervention arm at 8 am (B1). Patients were monitored for symptoms and signs of ethanol intoxication, including drowsiness, ataxia, slurred speech, loss of consciousness, or memory loss. In addition, monitoring for signs of hypoglycemia, blood pressure, and blood alcohol levels (if needed) was also done. We did not examine the interior of CVLs for drug precipitates because all patients still had the CVLs at the completion of the study.
Results
Between day "0" and day +7 posttransplant, most patients were on relatively fewer medications, thus allowing for a 2-hour CVL free time (lock time), and could take part in the study. All CVLs used in our patient population were made of silicone. A total of 11 patients participated in the study, contributing a total of 20 sets of data. The median age of the study subjects was 7 years, and no patient experienced any adverse event necessitating removal from the study. There were only 2 instances when the ethanol lock could not be fully withdrawn from the CVL; in each of these cases, the line was flushed with normal saline and returned to normal use with no notable adverse effects. Table 1 shows the  patient demographics and Table 2 the raw data of all 20 sets.
All 20 sets showed that the 8 am trough tacrolimus level (B1) in the exposed intervention arm (median = 30 ng/mL; range = 11.8-60 ng/mL) was significantly greater (P < 0.0001) than in the control arm (A1; median = 9.05 ng/mL, range = 2.7-18.9 ng/mL) and were contaminated as defined by the SCL above. The level of contamination in the exposed lumen, as measured by percentage difference from the control arm, ranged from 33% to 1011% (median = 238%; Tables 2 and 3) . Of the 20, 17 (85%) trough tacrolimus levels at 8 am from the intervention lumen were greater than the clinical reference range of 8 to 14 ng/mL. The 3 lumens that were within the clinical reference range were still significantly higher as compared with the levels from the control lumens (Table 2 , IDs 18-20). The 8 pm controls were not much different from the 8 am controls. Any difference here would reflect the inherent variability of the assay or the PK/PD of how the body uses tacrolimus. The median change between the 8 pm and 8 am controls was only 0.3 ng/mL over 12 hours.
Effect of Ethanol Lock Therapy
Figures 2 and 3 show a comparison of tacrolimus levels in the intervention arm (A) and the control arm (B) for each observation. After a 2-hour ethanol lock, the 8 pm trough tacrolimus levels (B2) decreased from the 8 am levels in all 20 (100%) observations, with measurements ranging from 3.3 to 24.2 ng/mL and a median of 12.14 ng/mL. The median percentage decrease from 8 am to 8 pm in the intervention lumen was 66% (range = 16% to 80%). Based on the laboratory analytical reference range and SCL as defined above, 8/20 (40%) lumens were considered decontaminated (Table 2) . However, based on the clinical reference range of tacrolimus (8-14 ng/mL), after the ethanol lock, 13/20 (65%) of the lumens were decontaminated, and only 7 were still above the clinical reference range. In 19/20 lumens, the 8 pm tacrolimus level fell by more than 30% as compared with the 8 am level in the intervention lumen (Table 2 , last column). Table 3 shows the comparison of control arms with the intervention arm using the tacrolimus levels at 8 am and 8 pm. Using the Wilcoxon's signed-rank test, the difference between the control and intervention results were no longer found to be statistically significant (P = 0.0826).
Out of 20, 12 (60%) sets had extremely high trough tacrolimus levels (≥30 ng/mL) at 8:00 am in the intervention arm (B1; Table 2 and Figure 2 ; ID: 1-12). After the 2-hour ethanol lock, median trough tacrolimus levels (B2) were 15.25 ng/mL (range = 7.7 to 24.2 ng/mL), representing a median percentage decrease of 71% (range = 40%-81% decrease) compared with its 8 am measurement. In 6/12 (50%) of these lumens, the levels decreased below the clinical reference range (8-14 ng/mL); in 4/12 lumens with levels still >14 ng/mL after the ethanol lock, the corresponding 8 pm control lumen level was also >14 ng/mL.
There was no correlation between the duration of CVL placement (the life of CVL) and degree of contamination of the white lumen (P = 0.8998) as shown in Figure 4A , and there was no correlation of the degree of CVL contamination with the amount/dose of tacrolimus infused through the white lumen (P = 0.6949) as shown in Figure 4B .
Discussion
CVL contamination with a CNI is a common problem encountered in patients undergoing allogeneic HSCT and institutions using intermittent tacrolimus infusions. The current solution is to check trough CNI levels via peripheral venipuncture for MDM and wait for the contamination to resolve itself with natural decay, which can take weeks or months. Replacing the contaminated CVL with a new CVL will expose the patient to additional risks of anesthesia, and surgery is not practically feasible. Hence, it is important to prevent contaminations with diligent nursing care and blood sampling for monitoring of CNI levels.
14 Although such a contaminated CVL by itself has no detrimental effects on the patient, it does affect the MDM process, causing indirect harm.
This study showed high tacrolimus levels in the intervention arm and confirmed that once a lumen is exposed to tacrolimus, it cannot be used to draw blood for reliable trough tacrolimus levels. Extremely high levels of contamination were seen in 60% of the lumens exposed to tacrolimus, though there was no correlation of the degree of contamination with the duration of CVL days or with the amount/dose of tacrolimus infused via that lumen. This is the first study of its kind to find a solution to the problem of CVL contamination with CNIs. We show that in 100% of the contaminated lumens, a 2-hour ethanol lock was effective in decreasing the degree of contamination, with 65% of the lumens being fully decontaminated. Even in lumens with extremely high levels of contamination (≥30 ng/mL), a 2-hour lock was able to fully decontaminate 50% of such lumens, and the remaining 50% showed a significant decrease. We did not use a second ethanol lock to further decontaminate such lumens; however, based on our encouraging results, a second ethanol lock may be safely used. Crnich et al 12 showed that prolonged exposure of CVLs to 70% ethanol for 10 weeks did not cause any damage to the mechanical integrity of the CVL material; hence, a second 2-hour ethanol lock, if needed, would be reasonable for lumens with extremely high degrees of contamination.
In case of suspicion that a CVL lumen may be contaminated, trough tacrolimus levels from both lumens should be compared with a peripheral blood sample. If the trough level from the peripheral blood and the CVL lumen(s) are within the SCL (as defined above), then that lumen should be considered safe and not contaminated. If the level from the lumen is more than 12.6% higher than the peripheral or the level from the unexposed lumen, then it should be considered contaminated, provided other clinical causes of a high level are ruled out. To help decontaminate a CVL, we propose the guidelines detailed in Table 4 .
Our study had some limitations. We were not able to keep a log of all the medications administered through both lumens to help evaluate the effect of increased flushes with medications on the degree of contaminations. Another limitation was the biological variation in the serum tacrolimus levels, which may have played a role by affecting the levels in the control and intervention arms simultaneously. In the 2 patients in whom we could not withdraw the ethanol lock, we did not measure the blood alcohol levels, though clinically they did not have any evidence of alcohol intoxication; in addition, we also did not test for dissolved polymer ingredients (from the CVL material) in the serum. Finally, our study had 20 data sets from 12 patients, which could be interpreted as a small study. However, with a power of 80%, we were able to show significant difference between the control arm and the intervention arm. 
Conclusion
A single 2-hour, 70% ethanol lock was effective in decontaminating the majority of the CVLs exposed to tacrolimus. The 2-hour ethanol lock had no adverse effects on patients, and its administration did not affect patient care. This new intervention would allow us to treat contaminated CVLs, change the current practice, improve therapeutic efficacy, and ultimately decrease the financial burden on patients and medical centers. 
